Skip to main content

Table 5 ISR difference scores (based on effect sizes [ES]a) of patients with a positive clinical diagnosis (depression, anxiety, obsessive-compulsive, somatoform and/or eating disorders) matched to according self-report ISR scores; total sample (n = 342) and comparison of patients with one year of treatment (n = 271) versus those with two years of treatment (n = 71)

From: Course of self-reported symptoms of 342 outpatients receiving medium- versus long-term psychodynamic psychotherapy

ISR scale Total sample Treatment over 1 year Treatment over 2 years
ES after completion of treatment ES after completion of treatment ES before completion of treatment ES after completion of treatment
ES (Tmax-T0)b ES (T1-T0) ES (T1-T0)c ES (T2-T0)d
ES (95 % CI) ES (95 % CI) ES (95 % CI) ES (95 % CI)
Depressive symptoms Positive clinical diagnosis of depressive disorder
n = 208
0.58 (0.44,0.71)
n = 159
0.56 (0.41,0.72)
n = 49
0.37 (0.09,0.65)
n = 49
0.61 (0.33,0.90)
Anxiety symptoms Positive clinical diagnosis of anxiety disorder
n = 128
0.45 (0.29,0.62)
n = 100
0.44 (0.26,0.63)
n = 28
0.44 (0.12,0.76)
n = 28
0.49 (0.11,0.87)
Obsessive-compulsive disorder symptoms Positive clinical diagnosis of obsessive-compulsive disorder
n = 43
0.54 (0.31,0.77)
n = 30
0.57 (0.30,0.84)
n = 13
0.23 (–0.24,0.71)
n = 13
0.47 (–0.05,0.99)
Somatoform symptoms Positive clinical diagnosis of somatoform disorder   
n = 94
0.31 (0.15,0.48)
n = 67
0.39 (0.18,0.60)*
n = 27
0.04 (–0.16,0.23)*
n = 27
0.13 (–0.10,0.37)
Eating disorder symptoms Positive clinical diagnosis of eating disorder
n = 68
0.29 (0.07,0.52)
n = 51
0.35 (0.10,0.60)*
n = 17
–0.21 (–0.58,0.16)*
n = 17
0.13 (–0.41,0.67)
  1. aEffect sizes (ES) interpreted as small (ES ~ 0.2), medium (ES ~ 0.5) or large (ES ~ 0.8) effects (Cohen, [27])
  2. bES based on Tmax (maximum), i.e. ES are based on the latest follow-up ISR data available, i.e. T1 (n = 271) and T2 (n = 71), respectively
  3. cES based on (T1-T0), i.e. this group’s first follow-up score
  4. dES based on (T2-T0), i.e. this group’s final follow-up score
  5. *Significant differences at p < .05 level (robust ANOVA, Brown-Forsythe for the comparison of patients with one year of treatment [n = 271] versus those with two years of treatment [n = 71], with the latter group having two follow-up scores, i.e. at T1 and at T2); patients with a positive diagnosis of respective symptom only